{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-090232","form_type":"8-K","ticker":"ATNM","cik":"0001388320","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-08-14T21:00:38+00:00","discovered_at":"2026-08-14T21:02:00.686583+00:00","generated_at":"2026-08-14T21:02:12.974300+00:00","sec_items":["3.01","7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Actinium gets NYSE plan acceptance through Nov 2027; adds Actimab-A patents and manufacturing","bullets":["NYSE Regulation accepted compliance plan; listing extended through Nov 27, 2027, maximum period under Section 1009.","Three US patents issued for Actimab-A: US 12,491,274 (sarcoma), US 12,539,340 (solid tumors), US 12,410,249 (low blast AML).","Canadian applications for venetoclax combo and CLAG-M combo advanced to pre-grant/allowed status.","Added second manufacturer under IND; will supply NCI CRADA and company studies with milestones from H2 2026.","Company remains non-compliant with Sections 1003(a)(ii) and (iii); delisting risk if plan not met by Nov 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-090232","json":"https://secwatch.observer/filing/0001213900-26-090232.json","markdown":"https://secwatch.observer/filing/0001213900-26-090232.md","text":"https://secwatch.observer/filing/0001213900-26-090232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026090232/0001213900-26-090232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026090232/ea0301890-8k_actinium.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T21:02:12.974300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}